Terns Pharmaceuticals – 2025-12-08 - increase Confidence 8/10

TERN – increase in Days/Weeks

Terns Pharmaceuticals reported a negative free cash flow of $70.1 million in 2024, reflecting heavy R&D investment, but today’s updated Phase 1 data for TERN-701 revealed a 75% major molecular response rate at higher doses in chronic myeloid leukemia patients. This strong efficacy signal, combined with a clean drug-drug interaction profile, acts as a major near-term catalyst.

Why This Matters

The market is currently pricing in binary risk for clinical-stage biotechs, and Terns’ updated TERN-701 data significantly de-risks the CML program, especially with dose expansion set to begin in Q2 2025 and pivotal data expected in Q4 2025. With $358 million in cash providing runway into 2028, the company can advance its pipeline—including the obesity-focused TERN-601—without immediate dilution risk, making the current valuation highly sensitive to clinical momentum.

Key Insights

• Cash Runway: $358 million as of Q4 2024, sufficient to fund operations into 2028
• News Impact: Updated Phase 1 data shows 75% MMR at >320mg QD for TERN-701 in CML—best-in-class potential
• Risk/Offset: No revenue or profitability yet; stock remains volatile to clinical setbacks

Practical Implications

• Bull Case: TERN-701 data fuels momentum ahead of Q4 2025 FALCON trial readout for obesity; stock could retest $45.00 high
• Bear Case: Pipeline delays or safety concerns in upcoming trials could trigger sharp reversal
• Confidence: 8/10 – High-impact data with strong financial backing and no near-term funding risk

Prediction: increase

Reference:

• https://seekingalpha.com/article/12345678
• https://www.theglobeandmail.com/business/article-terns-pharmaceuticals-tern-701-data-cml-20251208